366 related articles for article (PubMed ID: 9588554)
1. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means.
Kroll RA; Neuwelt EA
Neurosurgery; 1998 May; 42(5):1083-99; discussion 1099-100. PubMed ID: 9588554
[TBL] [Abstract][Full Text] [Related]
2. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
Doolittle ND; Anderson CP; Bleyer WA; Cairncross JG; Cloughesy T; Eck SL; Guastadisegni P; Hall WA; Muldoon LL; Patel SJ; Peereboom D; Siegal T; Neuwelt EA
Neuro Oncol; 2001 Jan; 3(1):46-54. PubMed ID: 11305417
[TBL] [Abstract][Full Text] [Related]
3. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers.
Kroll RA; Pagel MA; Muldoon LL; Roman-Goldstein S; Fiamengo SA; Neuwelt EA
Neurosurgery; 1998 Oct; 43(4):879-86; discussion 886-9. PubMed ID: 9766316
[TBL] [Abstract][Full Text] [Related]
4. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.
Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM
J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?
Kemper EM; Boogerd W; Thuis I; Beijnen JH; van Tellingen O
Cancer Treat Rev; 2004 Aug; 30(5):415-23. PubMed ID: 15245774
[TBL] [Abstract][Full Text] [Related]
6. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
Neuwelt EA; Hill SA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Lewis SE; Ehle AL; Beyer CW
Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316
[TBL] [Abstract][Full Text] [Related]
7. The effects of the Na(+)/Ca(++) exchange blocker on osmotic blood-brain barrier disruption.
Bhattacharjee AK; Nagashima T; Kondoh T; Tamaki N
Brain Res; 2001 May; 900(2):157-62. PubMed ID: 11334793
[TBL] [Abstract][Full Text] [Related]
8. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors.
Neuwelt EA; Rapoport SI
Fed Proc; 1984 Feb; 43(2):214-9. PubMed ID: 6692941
[TBL] [Abstract][Full Text] [Related]
9. Seizure-promoting effect of blood-brain barrier disruption.
Marchi N; Angelov L; Masaryk T; Fazio V; Granata T; Hernandez N; Hallene K; Diglaw T; Franic L; Najm I; Janigro D
Epilepsia; 2007 Apr; 48(4):732-42. PubMed ID: 17319915
[TBL] [Abstract][Full Text] [Related]
10. Effect of hyperosmotic solutions on human brain tumour vasculature.
Sato S; Kawase T; Harada S; Takayama H; Suga S
Acta Neurochir (Wien); 1998; 140(11):1135-41; disc 1141-2. PubMed ID: 9870058
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma.
Neuwelt EA; Howieson J; Frenkel EP; Specht HD; Weigel R; Buchan CG; Hill SA
Neurosurgery; 1986 Oct; 19(4):573-82. PubMed ID: 3097567
[TBL] [Abstract][Full Text] [Related]
12. Model for drug uptake by brain tumors: effects of osmotic treatment and of diffusion in brain.
Robinson PJ; Rapoport SI
J Cereb Blood Flow Metab; 1990 Mar; 10(2):153-61. PubMed ID: 2303532
[TBL] [Abstract][Full Text] [Related]
13. [Blood-brain barrier opening microcirculation in human brain tumor].
Sato S; Toya S; Otani M
No To Shinkei; 1985 Feb; 37(2):109-13. PubMed ID: 2988587
[TBL] [Abstract][Full Text] [Related]
14. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption.
Nilaver G; Muldoon LL; Kroll RA; Pagel MA; Breakefield XO; Davidson BL; Neuwelt EA
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9829-33. PubMed ID: 7568227
[TBL] [Abstract][Full Text] [Related]
15. Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy.
Rapoport SI
Expert Opin Investig Drugs; 2001 Oct; 10(10):1809-18. PubMed ID: 11772287
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption.
Hsieh CH; Chen YF; Chen FD; Hwang JJ; Chen JC; Liu RS; Kai JJ; Chang CW; Wang HE
J Nucl Med; 2005 Nov; 46(11):1858-65. PubMed ID: 16269600
[TBL] [Abstract][Full Text] [Related]
17. Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog.
Neuwelt EA; Frenkel EP; Rapoport S; Barnett P
Neurosurgery; 1980 Jul; 7(1):36-43. PubMed ID: 6774280
[TBL] [Abstract][Full Text] [Related]
18. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review).
van Vulpen M; Kal HB; Taphoorn MJ; El-Sharouni SY
Oncol Rep; 2002; 9(4):683-8. PubMed ID: 12066192
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of cold mannitol and Na(+)/Ca(2+) exchange blocker on blood-brain barrier opening.
Ikeda M; Bhattacharjee AK; Kondoh T; Nagashima T; Tamaki N
Biochem Biophys Res Commun; 2002 Mar; 291(3):669-74. PubMed ID: 11855842
[TBL] [Abstract][Full Text] [Related]
20. [Osmotic opening of the hematoencephalic barrier in experiments. Review].
Kozler P
Rozhl Chir; 2001 Aug; 80(8):393-6. PubMed ID: 11688240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
